Table 2.

Baseline characteristics at TCZ initiation Between GCA Diagnostic Groups

Characteristic, n (%)	Totald N=114	Biopsy provena,d N=60	Imaging onlyb,d N=41	Clinically diagnosedc N=13	P-value
Time GCA diagnosis to TCZ start					0.82
0–90 days	50 (43.9)	29 (48)	15 (37)	6 (46)
91–182 days	14 (12.3)	7 (12)	5 (12)	2 (15)
183–365 days	8 (7.0)	5 (8)	2 (5)	1 (8)
>365 days	42 (36.8)	19 (32)	19 (46)	4 (31)
Initial TCZ dose					0.82
High dosef	61/111 (55.0)	34/59 (58)	20/39 (51)	7 (54)
Low doseg	50/111 (45.0)	25/59 (42)	19/39 (49)	6 (46)
Prednisone dose at TCZ start e	30.0 [15.0–40.0]	30.0 [12.5–45.0]	20.0 [15.0–40.0]	40.0 [20.0–60.0]	0.13
Inflammatory Markers at TCZ start
ESR (mm/Hr)e	16.0 [7.0–27.0]	17.0 [6.0–27.0]	16.0 [8.0–24.0]	37.0 [11.0–50.0]	0.45h
C-Reactive Protein (mg/L)e	9.1 [3.0–26.0]	5.7 [3.0–23.5]	9.7 [4.0–19.1]	26.3 [5.0–39.8]	0.11h

ESR, erythrocyte sedimentation rate; GCA, giant cell arteritis; IQR, interquartile range; TCZ, tocilizumab

^aBiopsy proven with or without imaging

^bImaging showing evidence of large vessel vasculitis with either a negative biopsy or none performed

^cClinical diagnosis of GCA without imaging or biopsy positivity or none completed

^dIf data missing/unavailable, denominator listed if different from listed total

^emedian [interquartile range]

^fHigh dose= 8mg/kg intravenous every 4 weeks or 162 mg subcutaneous weekly

^gLow dose= 4mg/kg intravenous every 4 weeks or 162 mg subcutaneous every other week

^hKruskal-Wallis p-value